

Guideline Development Group (GDG)

Biographies of proposed members

Updated recommendations on antiretroviral therapy, management of vertical HIV transmission, and TB prevention in people living with HIV

18, 19, 20, 25, 26 February 2025 & 4, 5, 25, 26, 27 March 2025

Virtual sessions from 14:00h to 17:30h, CET

Disclaimer: *In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals (“Published Information”) being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.*

The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.

The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO’s conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.

Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO. The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publicly in accordance with WHO policies.

Dr Aleny Couto is the Public Health Deputy Director at Mozambique's Ministry of Health. She has dedicated her expertise to advancing the prevention, treatment, and control of HIV/AIDS in Mozambique. She has served in various roles, including as Director of the National Program for the Control of STI-HIV/AIDS (2013–2024). She is a permanent member of WHO's HIV technical working groups and the UNAIDS technical committee, contributing to global targets to eliminate HIV/AIDS.

Professor Alexandra Calmy is the head of the HIV/AIDS Unit at Hôpitaux Universitaires de Genève (HUG), Switzerland, where she plays an active role on the scientific advisory board of the Swiss HIV Cohort Study (SHCS). She has been a member of WHO technical working groups on HIV treatment management since 2010.

Professor Amgad Ali Alzahaby is an expert in hepatology, gastroenterology and infectious diseases, serving as a professor at Al-Azhar Faculty of Medicine in Cairo, Egypt. His expertise spans liver diseases, endoscopy, and HIV care.

Dr Anna Turkova is a research clinician at the Medical Research Council (MRC) Clinical Trials Unit at University College London and a Consultant Paediatrician at Great Ormond Street Hospital, London, UK. Dr Turkova serves as a co-chair of the WHO-led Paediatric Antiretroviral Working Group (PAWG) and is a member of the Global Accelerator for Paediatric Formulations Network (GAP-f). She contributed to the development of the WHO HIV Guidelines (2021) and the Penta/EACS HIV Guidelines (2016-2024).

Dr Anton Pozniak is a Consultant Physician at the Chelsea and Westminster Hospital in London, UK and was Director of the HIV service at this institution from 2008 until 2018. He is a Principal Investigator for a Test and Treat project in Tanzania. He is ART and TB Guidelines panel member of the European AIDS Clinical Society and BHIVA. He is a DSMB chair for MRC and PENTA studies.

Dr Beatriz Grinsztejn is an infectious disease physician and researcher with over 30 years of dedication to HIV prevention and care in Brazil. She is the Director of the FIOCRUZ STI/AIDS Prevention and Therapeutic Clinical Trials Unit, where she leads research focused on advancing the prevention, treatment, and care of HIV, STIs, and emerging infections. Dr Grinsztejn is the current President of the International AIDS Society (IAS).

Professor Charles W. Flexner, MD is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine in Baltimore, USA. He is also Professor of International Health at the Bloomberg School of Public Health. Dr Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis.

Dr Elaine Abrams is a global expert in HIV prevention and treatment, a professor at Columbia University, at New York, USA, and a founding member of ICAP at Columbia University where she is Senior Research Director. She leads various studies focusing on HIV prevention and treatment

for pregnant women, children, and families, and is a member of the WHO Pediatric Antiretroviral Working Group and Pregnancy Therapeutics Working Group.

Professor Francois Venter, MD, FCP, PhD is Executive Director of Wits Ezintsha at the University of the Witwatersrand, Johannesburg, South Africa. His work involves health systems research and clinical trials involving antiretrovirals. For over 20 years he has been an advisor to bodies such as the South African government, UNAIDS, and WHO, contributing to international, regional, and national HIV guidelines.

Dr Graeme Meintjes is a Professor of Medicine at the University of Cape Town (UCT), South Africa and Clinical Professor of Infectious Diseases at Queen Mary University of London (QMUL) in UK. He is an adult infectious diseases physician and clinician scientist. He leads a research programme that focuses on the clinical conditions affecting patients with advanced HIV disease including disseminated HIV-associated tuberculosis, the immune reconstitution inflammatory syndrome and cryptococcal meningitis. He has been chair or co-chair of the Southern African HIV Clinicians Society Adult ART Guidelines Committee for more than a decade and has participated in several WHO Guideline Development Groups in the fields of HIV, opportunistic infections, TB and Mpox.

Mrs Imelda Mahaka is the Executive Director with Pangaea Zimbabwe (PZAT). She has strong advocacy and stakeholder engagement experience, working with international, regional and local organizations and networks to strengthen demand, uptake, quality HIV prevention, care and treatment products/services. She sits on several trial committees that look at pediatric and adolescent treatment. She is a member of Afrocab Treatment Partnership, working towards empowered communities.

Professor Kelly Dooley, MD, PhD, MPH, Professor of Medicine, and Director of the Division of Infectious Diseases within the Department of Medicine at Vanderbilt University Medical Center (VUMC). As an infectious disease specialist and clinical pharmacologist, Dr Dooley maintains an active clinical practice in HIV care. Her research focuses on tuberculosis therapeutics with an emphasis on clinical trials of TB drugs and HIV/TB co-treatment, as well as clinical pharmacology of TB and HIV drugs. She is lead investigator for trials of therapeutics for drug-sensitive and drug-resistant TB, TB-HIV, and pediatric TB meningitis.

Dr Lameck Chinula is an Obstetrician and Gynecologist, and an Assistant Professor in the University of North Carolina (UNC) Department of Obstetrics and Gynecology Division of Global Women's Health, USA. Based at UNC Project-Malawi in Lilongwe, Malawi, he serves as a Clinical Research Site Leader for the UNC Global HIV Clinical Trials Unit and supports a broad portfolio of clinical research in Malawi. He has over 10 years' research experience focused on cervical cancer prevention and HIV prevention. He played a key role in the development of the Cervical Cancer Control Strategy and Guidelines for Service Providers within the Malawi Ministry of Health.

Dr Lindiwe Mvusi is the Director for TB control and management, National Department of Health, in Johannesburg, South Africa. Dr Mvusi is a medical practitioner with post graduate training in occupational and public health. She has over 20 years' experience in clinical practice

and public health working in both the private and public sectors. She has vast experience in policy and guideline development, training, monitoring and evaluation of policy implementation and overall coordination of the TB programme.

Dr Lloyd B. Mulenga (BScHb, MBChB, MSc, MMed, PhD) is an Internal Medicine and Infectious Diseases Physician with duo-appointment as 1) Director of the Infectious Diseases for the Zambia Ministry of Health and 2) Professor of Infectious Diseases at the University of Zambia (UNZA) School of Medicine (SOM) and its accredited teaching hospital, the University Teaching Hospital (UTH).

Dr Lynne M. Mofenson, MD is a pediatric infectious disease specialist, who has spent her career doing research on prevention and treatment of pediatric and maternal HIV infection. In 2014, she retired from the U.S. National Institutes of Health, where she led many of the key clinical trials on prevention of mother to child transmission and pediatric and maternal treatment. She chaired the U.S. Public Health Service (PHS) panel guidelines for treatment of pregnant women with HIV and prevention of perinatal transmission 1997-2014 and continues as current member; she also chaired the U.S. PHS Panel on pediatric antiretroviral treatment 1998-2014, and continued as a member through 2023.

Dr Mohamed Chakroun is a medical doctor and infectious diseases specialist, serving as a Professor at the Faculty of Medicine of Monastir, Tunisia. He has provided technical support to Tunisia's National AIDS Program (NAP), WHO's HIV/AIDS, STIs & Hepatitis Unit (Cairo), and UNICEF's Regional Office (Amman) on initiatives such as antiretroviral therapy, HIV prevention, and the triple elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B. Dr Chakroun contributes to global health through memberships in WHO's Guideline Development Group on antiretrovirals, HIVResNet, the Global Validation Advisory Committee for triple elimination, and other advisory groups.

Dr Moherndran Archary leads the Paediatric Infectious Diseases Unit at the University of KwaZulu-Natal -Nelson R Mandela School of Medicine in South Africa, where he is Senior Specialist in Paediatric Infectious Diseases. Dr Archary has over 20 years of experience working with international research networks, including PACTG, IMPAACT, and PENTA. Dr Archary has been extensively involved with the WHO, co-chairing the Paediatric ARV Working Group (PAWG) and serving as a member of various committees, including the HIV Guideline Committee, Adolescent Service Delivery Working Group, and HIV Resistance Network (HIV ResNet). He also contributes to the DHHS guidelines as an advisor on the Cryptococcal Management chapter.

Dr Nagalineswaran Kumarasamy is the Chief & Director of Infectious Diseases Medical Centre at Voluntary Health Services (VHS) Hospital in Chennai, India and directs the clinic which provides medical care for persons with HIV, Viral Hepatitis, Tuberculosis, COVID and other Infectious Diseases in Chennai, Southern India. Dr Kumarasamy is the Director of the Chennai Antiviral Research and Treatment (CART) Clinical Research Site which conducts Therapeutics and Biomedical prevention clinical trials in HIV, Viral Hepatitis, Tuberculosis, COVID and other

Infectious Diseases Dr Kumarasamy is an advisor and expert panel member WHO ARV Treatment guidelines committees and a Clinical advisor to Clinton Health Access Initiative.

Dr Ni Ni Tun is currently a PhD fellow at the University of Antwerp working in collaboration with the Institute of Tropical Medicine and the University of Oxford on interventions to address gaps in HIV prevention and treatment for Key Affected Populations (KAPs) in Myanmar. She began her career as the HIV/TB National Coordinator with Médecins Sans Frontières (MSF) in Myanmar in 2003.

Dr Othoman Mellouk is the program lead of the intellectual property and access to medicines program at ITPC. He coordinates the “Make Medicines Affordable” campaign, covering 24 low and middle-income countries across Latin America, Asia, Eastern Europe and Central Asia and Africa.

Dr Pedro Cahn is the Scientific Director of Fundación Huésped, a leading non-governmental organization dedicated to public health research, advocacy, and education. Dr Cahn has contributed extensively to clinical trials, academic publications, and global initiatives, collaborating with international organizations such as the WHO and UNAIDS.

Mrs Polly Clayden has been an HIV treatment activist for over 25 years. She is internationally recognized as a leading community journalist and has led reporting on these and other aspects of care in covering all major conferences and publications. She co-founded HIV i-Base, a community organisation based in London, UK. She has expertise in many aspects of HIV research, including HIV treatment optimization for low-income countries, women’s health, pediatric care, and the prevention of mother-to-child transmission. Polly has served on many trial steering committees, guidelines and working groups including LEAP (Long-Acting/Extended Release Antiretroviral Research Resource Program), the PENTA ID Network and the British HIV Association (BHIVA) pregnancy guidelines.

Dr Rossana A. Ditangco is a physician and public health expert with extensive experience in infectious disease research and global health initiatives. Dr Ditangco currently serves as the Research Chief at the Research Institute for Tropical Medicine (RITM) in the Philippines.

Dr Shahin Lockman is an infectious-disease internist and has conducted clinical investigation and training primarily focused on HIV with colleagues in Botswana since 1996. One of her research focus areas is the safety and efficacy of antiretroviral drugs used for HIV treatment and prevention in pregnancy, including through clinical trials during pregnancy and postpartum and studies of the health and neurodevelopment of HIV-exposed children. She has worked with the WHO and IMPAACT network since 2019 on an initiative to accelerate access to high-quality pregnancy and lactation data for antiretrovirals, including through creation of an open-access pregnancy research toolkit hosted by the WHO.

Professor Thanyawee Puthanakit, M.D., M.H.S., is a Professor of Pediatrics at Chulalongkorn University in Bangkok, Thailand, specializing in pediatric infectious diseases and vaccines. Dr Puthanakit has had roles in global health initiatives, including serving on WHO committees and

contributing to international guidelines for pediatric HIV treatment in resource-limited settings. As the Director of the Center of Excellence for Pediatric Infectious Diseases and Vaccines at Chulalongkorn University, she leads innovative clinical research and collaborates with global consortia such as PENTA and the EPIICAL Consortium.

Professor Thuy Le is an Associate Professor of Medicine, Molecular Genetics and Microbiology at Duke University School of Medicine where she co-directs the Clinical Core of the Duke Center for AIDS Research and the NIH-sponsored Tropical Medicine Research Center (TMRC) for Talaromycosis in Vietnam. Dr Le is a member of numerous WHO Guidelines Committees on HIV Therapy, Management of Advanced HIV Disease, and Management of AIDS-associated Cryptococcal Meningitis and Histoplasmosis.

Professor Victor Musiime, MBChB, MMed, is a pediatrician based in Kampala, Uganda. He works as an Associate Professor and Head, Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences at Makerere University, and a Senior Research Consultant at Joint Clinical Research Centre (JCRC). He has also been on technical working groups and advisory boards with organizations at international, regional and national levels, including the WHO, the African Network for the Care of Children and Adolescents (Anecca) and the Ministry of Health in Uganda.